Verdure Sciences Launches Longvida, Next Generation Curcumin Now Available
The platform behind Longvida is the proprietary Solid Lipid Curcumin Particle (SLCP) Technology, based on the results of numerous trials in live pharmacokinetic and pharmacodynamic models.
Oct 19 2010 --- Verdure Sciences announces the launch of Longvida Optimized Curcumin. Developed by an elite group of neuroscientists at the University of California, Los Angeles (UCLA), patent-pending Longvida is the result of years of painstaking research on hundreds of different formulas. Uniquely shown to address the top three pathways affecting age-related brain health, Longvida is currently the subject of widespread clinical research trials and funding from the National Institutes of Health (NIH).
The platform behind Longvida is the proprietary Solid Lipid Curcumin Particle (SLCP) Technology, based on the results of numerous trials in live pharmacokinetic and pharmacodynamic models. In published, peer-reviewed human research, Longvida was shown to absorb into human plasma 65 times greater than non-optimized curcumin. These blood levels are thought to correlate to areas of health where conventional means may have fallen short.
"The pedigree of Longvida is substantial, but we believe that research should be independent and speak for itself," said Blake Ebersole, Technical Director at Verdure Sciences. “Through our partnership with renowned researchers, we aim to set a high standard of scientific rigor and blaze new paths of discovery with Longvida.”
Manufactured under GMP standards in an NSF International- and ISO-certified facility, patent-pending Longvida Optimized Curcumin adheres to the highest quality standards, and does not contain volatile oils or metabolic inhibitors.
